Article Correctness Is Author's Responsibility: Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock as top-line results of AdrenOSS-2 Phase II Study indicate

(sphingotec GmbH) AdrenOSS-2 Phase II trial shows that modulating the Adrenomedullin plasma level with the therapeutic antibody Adrecizumab demonstrates an improvement of survival in patients with septic shock.